Literature DB >> 26316568

Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

J Hodel1, O Outteryck2, S Verclytte3, V Deramecourt4, A Lacour2, J-P Pruvo5, P Vermersch2, X Leclerc5.   

Abstract

We investigated the brain magnetic susceptibility changes induced by natalizumab-associated progressive multifocal leukoencephalopathy. We retrospectively included 12 patients with natalizumab-progressive multifocal leukoencephalopathy, 5 with progressive multifocal leukoencephalopathy from other causes, and 55 patients with MS without progressive multifocal leukoencephalopathy for comparison. MR imaging examinations included T2* or SWI sequences in patients with progressive multifocal leukoencephalopathy (86 examinations) and SWI in all patients with MS without progressive multifocal leukoencephalopathy. Signal abnormalities on T2* and SWI were defined as low signal intensity within the cortex and/or U-fibers and the basal ganglia. We observed T2* or SWI signal abnormalities at the chronic stage in all patients with progressive multifocal leukoencephalopathy, whereas no area of low SWI signal intensity was detected in patients without progressive multifocal leukoencephalopathy. Among the 8 patients with asymptomatic natalizumab-progressive multifocal leukoencephalopathy, susceptibility changes were observed in 6 (75%). The basal ganglia adjacent to progressive multifocal leukoencephalopathy lesions systematically appeared hypointense by using T2* and/or SWI. Brain magnetic susceptibility changes may be explained by the increased iron deposition and constitute a useful tool for the diagnosis of progressive multifocal leukoencephalopathy.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26316568      PMCID: PMC7964269          DOI: 10.3174/ajnr.A4436

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  11 in total

1.  Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.

Authors:  Nicholas F Blair; Bruce J Brew; Jean-Pierre Halpern
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

Authors:  Mike P Wattjes; Lonneke Verhoeff; Willemijn Zentjens; Joep Killestein; Erik T van Munster; Frederik Barkhof; Jeroen J J van Eijk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-05-21       Impact factor: 10.154

3.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

Review 4.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 5.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

Review 6.  Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient.

Authors:  E O Major; G S Ault
Journal:  Curr Opin Neurol       Date:  1995-06       Impact factor: 5.710

Review 7.  The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Mike P Wattjes; Nancy D Richert; Joep Killestein; Marlieke de Vos; Esther Sanchez; Petur Snaebjornsson; Diego Cadavid; Frederik Barkhof
Journal:  Mult Scler       Date:  2013-11-05       Impact factor: 6.312

8.  Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Daniel Pelletier; Diego Cadavid; Achim Gass; Nancy D Richert; Ernst-Wilhelm Radue; Massimo Filippi
Journal:  Ann Neurol       Date:  2012-11       Impact factor: 10.422

9.  Multiple sclerosis: improved identification of disease-relevant changes in gray and white matter by using susceptibility-based MR imaging.

Authors:  David A Rudko; Igor Solovey; Joseph S Gati; Marcelo Kremenchutzky; Ravi S Menon
Journal:  Radiology       Date:  2014-05-14       Impact factor: 11.105

10.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Authors:  Tuan Dong-Si; Sandra Richman; Mike P Wattjes; Made Wenten; Sarah Gheuens; Jeffrey Philip; Shoibal Datta; James McIninch; Carmen Bozic; Gary Bloomgren; Nancy Richert
Journal:  Ann Clin Transl Neurol       Date:  2014-10-09       Impact factor: 4.511

View more
  12 in total

1.  REPLY.

Authors:  J Hodel; O Outteryck; S Verclytte; V Deramecourt; A Lacour; J-P Pruvo; P Vermersch; X Leclerc
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-03       Impact factor: 3.825

2.  Low Signals on T2* and SWI Sequences in Patients with MS with Progressive Multifocal Leukoencephalopathy.

Authors:  P Labauge; C Carra-Dalliere; X Ayrignac; N Menjot de Champfleur
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-03       Impact factor: 3.825

Review 3.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

Review 4.  Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.

Authors:  Eric M L Williamson; Joseph R Berger
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

5.  Susceptibility-Based Neuroimaging: Standard Methods, Clinical Applications, and Future Directions.

Authors:  Salil Soman; Jose A Bregni; Berkin Bilgic; Ursula Nemec; Audrey Fan; Zhe Liu; Robert L Barry; Jiang Du; Keith Main; Jerome Yesavage; Maheen M Adamson; Michael Moseley; Yi Wang
Journal:  Curr Radiol Rep       Date:  2017-02-14

Review 6.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

Review 7.  Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.

Authors:  S Richard Dunham; Robert Schmidt; David B Clifford
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

8.  Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the gray-white matter junction correlates with iron-enriched macrophages.

Authors:  Kedar R Mahajan; Moein Amin; Matthew Poturalski; Jonathan Lee; Danielle Herman; Yufan Zheng; Caroline Androjna; Mark Howell; Robert J Fox; Bruce D Trapp; Stephen E Jones; Kunio Nakamura; Daniel Ontaneda
Journal:  Mult Scler       Date:  2021-03-22       Impact factor: 5.855

9.  Low-signal Intensity Rims along the Cerebral Cortex and U-fibers on Susceptibility-weighted Imaging in Progressive Multifocal Leukoencephalopathy.

Authors:  Yuki Arita; Hirokazu Fujiwara; Jun Kurasawa; Suketaka Momoshima; Tsubasa Takizawa; Masahiro Jinzaki
Journal:  Magn Reson Med Sci       Date:  2017-06-08       Impact factor: 2.471

10.  Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study.

Authors:  Giuseppe Pontillo; Sirio Cocozza; Roberta Lanzillo; Pasquale Borrelli; Anna De Rosa; Vincenzo Brescia Morra; Enrico Tedeschi; Giuseppe Palma
Journal:  Front Neurol       Date:  2017-06-19       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.